Mass Spectrometry-Based Approaches for Treating Human Diseases and Diagnostics (Advances in Experimental Medicine and Biology, 1443) 3031506235, 9783031506239

Table of contents :
Preface
Contents
Chapter 1: Isolation of Extracellular Vesicles Using Titanium Dioxide Microspheres
1.1 Introduction
1.1.1 Extracellular Vesicle Biosynthesis and Biological Functions in Diseases
1.1.2 Omics Science Approaches for Extracellular Vesicle Characterization
1.2 Material and Methods
1.2.1 Plasma Samples
1.2.2 Enrichment of Plasma EVs Using TiO2 Microspheres
1.2.3 EV Morphological Characterization by Transmission Electron Microscopy and Nanoparticle Tracking Analysis (NTA)
1.2.3.1 For NTA Analysis
1.2.3.2 For TEM Analysis
1.2.4 EV Plasma Proteome Identification Using MALDI-TOF MS and LC-MS/MS
1.2.4.1 For the MALDI-TOF MS Approach
1.2.4.2 For LC-MS/MS Analysis
1.2.5 Bioinformatics Analysis of Mass Spectrometry-Based Proteomics (LC-MS/MS)
1.3 Results of the EV Morphological Characterization and Proteome Identification
1.4 Conclusion
References
Chapter 2: Glycosort: A Computational Solution to Post-process Quantitative Large-Scale Intact Glycopeptide Analyses
2.1 Introduction
2.1.1 Glycosort: A Post-processing Tool for Large-Scale Quantitative Glycoproteomic Data
2.2 Data Processing
2.3 How to Use the Script
2.4 Conclusions
References
Chapter 3: Applications of Mass Spectrometry in the Characterization, Screening, Diagnosis, and Prognosis of COVID-19
3.1 Introduction
3.2 SARS-CoV-2: Understanding the Molecular Structure, the Mechanism of Viral Replication, and Pathogenesis
3.3 MS-Based Analytical Approaches Provide Details on SARS-CoV-2 Molecular Structure and Virus-Host Interactions
3.4 MS as a Major Tool for Understanding the Biological Properties of the Variants and Their Potential Impact on Public Health
3.5 MALDI-TOF Mass Spectrometry in the Identification of Post-translational Modifications in SARS-CoV-2 and Other Viruses
3.6 Mass Spectrometry-Based Approaches to Epitope Mapping: A Powerful Tool for Identifying the Specific Regions on a Protein That Are Recognized by the Immune System
3.7 Clinical Peptidomics by MALDI-TOF-MS: Diagnosis and Prognosis
3.7.1 Detection and Diagnosis
3.7.2 Prognosis Models for COVID-19 Outcomes
3.8 Optimization of Sample Preparation for Plasma Clinical Peptidomics by MALDI-TOF-MS
3.8.1 MALDIquant General R Script
3.8.2 Data Analysis with MALDIquant
3.9 Final Considerations
References
Chapter 4: Proteomics and Metabolomics in Congenital Zika Syndrome: A Review of Molecular Insights and Biomarker Discovery
4.1 Introduction
4.2 Zika Virus
4.2.1 Epidemiology, Transmission, and Pathology
4.2.2 ZIKV Composition
4.2.3 Viral Cycle
4.2.3.1 ZIKV Binding and Entry
4.2.3.2 ZIKV Translation, Replication, and Assembly
4.2.3.3 ZIKV Maturation and Secretion
4.2.4 ZIKV Post-translational Modifications in Viral Pathogenicity
4.2.5 Vertical Transmission
4.3 Congenital Zika Syndrome
4.3.1 Pathology and Diagnosis
4.3.2 Blood-Brain Barrier
4.3.3 In Vivo Models for CZS Studies
4.4 Proteomics and Metabolomics Studies Applied to Congenital Zika Syndrome
4.4.1 Mechanism for ZIKV Brain Infection and CZS Development
4.4.1.1 Affinity Purification Coupled with Mass Spectrometry (AP-MS)
4.4.1.2 Cross-Linking Coupled with Mass Spectrometry (XL-MS)
4.4.1.3 Quantitative Proteomics and Metabolomics
4.4.1.3.1 Proteomics Studies
4.4.1.3.2 Metabolomics Studies
4.4.2 PTMs Associated with ZIKV Brain Infection and CZS Development
4.4.3 Precision Medicine and CZS Biomarkers
4.4.3.1 Precision Medicine and Biomarker Concepts
4.4.3.2 Biomarkers and MS-Based Proteomics
4.4.3.3 CZS Biomarker Studies
4.5 Conclusions
References
Chapter 5: Mass Spectrometry Applications to Study Human Microbiome
5.1 Impact of Human Microbiome on Health State
5.2 Mass Spectrometry at a Glance
5.3 Approaches for Dissecting the Functional Contribution of the Gut Microbiome to Metabolic Disease
5.4 Mass Spectrometric Approaches Applied to Bacterial Identification
5.5 Mapping Human Microbiome Drug Metabolism
5.6 Conclusion and Future Perspectives
References
Chapter 6: Neuroproteomics: Unveiling the Molecular Insights of Psychiatric Disorders with a Focus on Anxiety Disorder and Depression
6.1 Introduction
6.2 Anxiety Disorders
6.2.1 Neurobiology
6.2.2 Pharmacological Therapy of Anxiety Disorders
6.3 Depression Disorders
6.3.1 Neurobiology
6.3.2 Pharmacological Therapy of Depressive Disorders
6.4 Depression-like and Anxiety-like Animal Models and Tests
6.4.1 Chronic Mild Stress
6.4.2 Social Defeat
6.4.3 Learned Helplessness
6.4.4 Neonatal Maternal Separation
6.4.5 Genetic Modification
6.5 Behavioral Tests for Validation in Animal Models
6.5.1 Open Field Test
6.5.2 Forced Swim Test
6.5.3 Light/Dark Box
6.5.4 Sucrose Preference Test
6.6 Omics Studies
6.6.1 Omics of the Chronic Mild Stress Model
6.6.2 Omics of the Social Defeat Model
6.6.3 Omics of the Learned Helplessness Model
6.6.4 Neonatal Maternal Separation Model
6.6.5 Omics in the Genetic Modification Model
6.6.6 Omics in Anxiety- and Depression-like Treatments
6.7 Conclusions
References
Chapter 7: Proteomic-Based Studies on Memory Formation in Normal and Neurodegenerative Disease-Affected Brains
7.1 Introduction
7.2 Memory
7.3 Proteomics and Memory
7.4 Proteomics and Neurodegenerative Disease
7.5 Alzheimer’s Disease
7.6 Parkinson’s Disease
7.7 Conclusions
References
Chapter 8: Cardioproteomics: Insights on Cardiovascular Diseases
8.1 Introduction
8.2 Atherosclerosis
8.2.1 Endothelial Dysfunction
8.2.2 Inflammation
8.2.3 Calcification
8.3 Coronary Artery Disease
8.3.1 Myocardial Infarction
8.4 Cardiomyopathy
8.4.1 Hypertrophic Cardiomyopathy
8.4.2 Dilated Cardiomyopathy
8.5 Conclusions
References
Chapter 9: Kidney Disease and Proteomics: A Recent Overview of a Useful Tool for Improving Early Diagnosis
9.1 Introduction
9.2 Diabetic Kidney Disease and Proteomics
9.3 IgA Nephropathy and Proteomics
9.4 Chronic Kidney Disease of Unknown Origin (CKDu) and Proteomics
9.5 Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Proteomics
9.6 Lupus Nephritis and Proteomics
9.7 Hypertensive Nephropathy and Proteomics
9.8 COVID-19-Associated AKI and Proteomics
9.9 Conclusions
References
Chapter 10: Multi-omics Investigations in Endocrine Systems and Their Clinical Implications
10.1 Proteomics in Diabetes Research
10.1.1 Proteomics and Type 1 Diabetes
10.1.2 Proteomics and Type 2 Diabetes
10.2 Hypothalamic-Pituitary-Thyroid Axis
10.2.1 The Use of Proteomic Approach in Studies of the HPT Axis
10.2.2 Thyroid Cancer and Biomarkers
10.3 Proteomics and the Reproductive System
10.3.1 Network Controlling Male and Female Reproductive Systems
10.3.2 Reproductive Tissue-Specific Proteome
10.3.3 Proteomic Approach Within Infertility
10.3.4 Proteomic Approach in Reproductive System Cancers
10.4 Renin-Angiotensin System and Proteomics
10.5 Omics and Circadian Rhythmicity
10.6 Conclusion
References
Chapter 11: Omics to Unveil Diabetes Mellitus Pathogenesis and Biomarkers: Focus on Proteomics, Lipidomics, and Metabolomics
11.1 Introduction
11.2 Omics in Diabetes Mellitus Diagnostics
11.2.1 Proteomics
11.2.2 Metabolomics
11.2.3 Lipidomics
11.3 Conclusions
References
Chapter 12: Proteomics: Unraveling the Cross Talk Between Innate Immunity and Disease Pathophysiology, Diagnostics, and Treatment Options
12.1 Introduction
12.2 Infectious Diseases
12.2.1 Diagnostics
12.2.2 Treatment
12.3 Cancer
12.3.1 Diagnosis
12.3.2 Treatment
12.4 Autoimmune Diseases
12.4.1 Diagnosis
12.4.2 Treatment
12.5 Neurodegenerative Diseases
12.6 Conclusions
References
Chapter 13: Applications of Proteomics in Probiotics Having Anticancer and Chemopreventive Properties
13.1 Proteomics for Probiotic Traits
13.2 Probiotics and Their Applications
13.3 Proteomics for Anticancer Probiotics
13.3.1 Proteomics for Anticancer Lactic Acid Bacteria
13.3.2 Proteomics for Lactococcus lactis NCDO 2118
13.3.3 Proteomics for Lactobacillus acidophilus
13.3.4 Proteomics for Lactobacillus fermentum NCDC
13.3.5 Proteomics for Surface-Exposed Proteins in Anticancer Probiotics
13.4 Proteomics for Chemopreventive Probiotics
13.5 Proteomics for Anti-inflammatory Probiotics
13.6 Proteomics for Probiotic Formulations and Quality Control
13.7 Conclusions
References
Chapter 14: Mass Spectrometry-Based Characterization of Protein Aggregates in Tissues and Biofluids
14.1 Introduction
14.2 Methodology
14.2.1 Isolation of Protein Aggregates
14.2.2 Sample Preparation for Mass Spectrometry Analysis
14.2.3 Mass Spectrometry Analysis
14.2.4 Database Search
14.2.5 Transmission Electron Microscopy (TEM) Analysis
14.2.6 Western Blotting
14.3 Results
14.3.1 Aggregates Isolated from Human Plasma Show a Diversity of Protein Functions
14.3.2 Neurodegeneration-Related Proteins and Exosomes Are Isolated in the Pellet Fraction of Human Plasma
14.3.3 Isolated Protein Aggregates from Mouse Brain Are Composed of a Variety of Proteins Associated with Neurodegenerative Diseases
14.4 Conclusions
References
Index

Polecaj historie

T Regulatory Cells in Human Health and Diseases (Advances in Experimental Medicine and Biology, 1278) 981156406X, 9789811564062

This book addresses one of the major challenges of immunology today that is being directed to the translation of the rap

109 62 9MB Read more

Retinal Degenerative Diseases XIX: Mechanisms and Experimental Therapy (Advances in Experimental Medicine and Biology, 1415) [1st ed. 2023] 3031276809, 9783031276804

This book contains the proceedings of the XVIII International Symposium on Retinal Degeneration (RD2018). A majority of

202 58 82MB Read more

Carotenoids: Biosynthetic and Biofunctional Approaches: Biosynthetic and Biofunctional Approaches (Advances in Experimental Medicine and Biology, 1261) 981157359X, 9789811573590

This book provides a comprehensive overview of carotenoid biosynthesis by different organisms, including bacteria, archa

117 117 13MB Read more

Extracellular Vesicles in Cardiovascular and Metabolic Diseases (Advances in Experimental Medicine and Biology, 1418) [1st ed. 2023] 9819914426, 9789819914425

This book provides the latest research progress on Extracellular vesicles (EVs) in cardiovascular and metabolic diseases

156 111 12MB Read more

Extracellular Vesicles in Cardiovascular and Metabolic Diseases (Advances in Experimental Medicine and Biology, 1418) [1st ed. 2023] 9819914426, 9789819914425

This book provides the latest research progress on Extracellular vesicles (EVs) in cardiovascular and metabolic diseases

206 128 5MB Read more

GeNeDis 2020: Genetics and Neurodegenerative Diseases (Advances in Experimental Medicine and Biology Book 1339) 9783030787875, 9783030787868, 3030787877

146 7 55MB Read more

Targeting Lysine Demethylases in Cancer and Other Human Diseases (Advances in Experimental Medicine and Biology, 1433) [1st ed. 2023] 3031381750, 9783031381751

This book provides a comprehensive summary of our current knowledge on lysine demethylases, a class of epigenetic regula

145 89 6MB Read more

Targeting Lysine Demethylases in Cancer and Other Human Diseases (Advances in Experimental Medicine and Biology, 1433) [1st ed. 2023] 3031381750, 9783031381751

This book provides a comprehensive summary of our current knowledge on lysine demethylases, a class of epigenetic regula

147 68 18MB Read more

Circadian Clock in Brain Health and Disease (Advances in Experimental Medicine and Biology, 1344) 3030811468, 9783030811464

In this book, leading experts in the field review how circadian rhythms impact the brain. An essential function of mamma

115 20 5MB Read more

Robotics in Healthcare: Field Examples and Challenges (Advances in Experimental Medicine and Biology, 1170) 9783030242299, 3030242293

The work is a collection of contributions resulting from R&D efforts originated from scientific projects involving a

335 103 7MB Read more